

## Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide

Max Jan, Irene Scarfò, Rebecca C. Larson, Amanda Walker, Andrea Schmidts, Andrew A. Guirguis, Jessica A. Gasser, Mikolaj Slabicki, Amanda A. Bouffard, Ana P. Castano, Michael C. Kann, Maria L. Cabral, Alexander Tepper, Daniel E. Grinshpun, Adam S. Sperling, Taeyoon Kyung, Quinlan L. Sievers, Michael E. Birnbaum, Marcela V. Maus and Benjamin L. Ebert

*Sci Transl Med* **13**, eabb6295.  
DOI: 10.1126/scitranslmed.abb6295

### Flipping the switch on T cells

Cell-based treatments such as chimeric antigen receptor (CAR) T cells have been finding increasing applications against cancer and other disorders. However, these treatments can have side effects, and it is difficult to stop the activity of an overactive cell-based therapy once it is inside a patient. To improve regulation of CAR T cell treatment, Jan *et al.* developed a switch-based system for activating and inactivating these cells. T cells with an OFF switch were deactivated using the drug lenalidomide, whereas those with an ON switch required both lenalidomide and a target antigen for activation, allowing control over the timing of T cell activation.

ARTICLE TOOLS	<a href="http://stm.sciencemag.org/content/13/575/eabb6295">http://stm.sciencemag.org/content/13/575/eabb6295</a>
SUPPLEMENTARY MATERIALS	<a href="http://stm.sciencemag.org/content/suppl/2021/01/04/13.575.eabb6295.DC1">http://stm.sciencemag.org/content/suppl/2021/01/04/13.575.eabb6295.DC1</a>
RELATED CONTENT	<a href="http://stm.sciencemag.org/content/scitransmed/11/499/eaau5907.full">http://stm.sciencemag.org/content/scitransmed/11/499/eaau5907.full</a> <a href="http://stm.sciencemag.org/content/scitransmed/11/485/eaau7746.full">http://stm.sciencemag.org/content/scitransmed/11/485/eaau7746.full</a> <a href="http://stm.sciencemag.org/content/scitransmed/8/355/355ra116.full">http://stm.sciencemag.org/content/scitransmed/8/355/355ra116.full</a> <a href="http://stm.sciencemag.org/content/scitransmed/9/399/eaau0984.full">http://stm.sciencemag.org/content/scitransmed/9/399/eaau0984.full</a> <a href="http://science.sciencemag.org/content/sci/371/6526/300.full">http://science.sciencemag.org/content/sci/371/6526/300.full</a> <a href="http://science.sciencemag.org/content/sci/early/2021/02/24/science.abc1855.full">http://science.sciencemag.org/content/sci/early/2021/02/24/science.abc1855.full</a>
REFERENCES	This article cites 56 articles, 20 of which you can access for free <a href="http://stm.sciencemag.org/content/13/575/eabb6295#BIBL">http://stm.sciencemag.org/content/13/575/eabb6295#BIBL</a>
PERMISSIONS	<a href="http://www.sciencemag.org/help/reprints-and-permissions">http://www.sciencemag.org/help/reprints-and-permissions</a>

Use of this article is subject to the [Terms of Service](#)

*Science Translational Medicine* (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works